New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

New findings from MS PATHS show that treatment with TYSABRI® (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus® (ocrelizumab) Real-world data from VUMERITY® (diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on […] Lire la suite »

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs More than 500,000 individuals worldwide living with multiple sclerosis (MS) have been treated with TECFIDERA, which has a well-established safety and efficacy profile Biogen’s expansion in China now includes treatment options approved […] Lire la suite »

Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021

CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting. AAN Poster Presentation Details: Saturday, […] Lire la suite »

SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies

Results from preclinical, proof-of-concept studies were presented at the 2021 AACR Annual Meeting Results demonstrate strong potential of SOT102 to eliminate tumor cells in a target-specific manner First-in-human study in gastric and pancreatic cancer patients with expected launch in early 2022 PRAGUE, Czech Republic, April 12, 2021 (GLOBE NEWSWIRE) — […] Lire la suite »

NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma who Failed Platinum-Containing Chemotherapy or Progressed within 12 Months of Neoadjuvant or Adjuvant Platinum-Containing Chemotherapy

SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment […] Lire la suite »

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA® (tocilizumab) Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost savings and healthcare sustainability CAMBRIDGE, Mass. and GUANGZHOU, China, April 08, 2021 (GLOBE NEWSWIRE) — […] Lire la suite »

AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases

OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious adverse events, and paving the way […] Lire la suite »

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis

TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients’ individual preferences and needs The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting The approval adds to Biogen’s strong MS […] Lire la suite »

SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting

PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) — SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting. The presentation focuses on preclinical data describing SOT102 which is intended for the […] Lire la suite »

LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors

UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCEs) to transform cancer therapy, today announced that Karen J. Wilson has been appointed to its Board of Directors and […] Lire la suite »

Junshi Biosciences Announces Full Year 2020 Financial Results And Provides Corporate Updates

SHANGHAI, China, March 30, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced financial results for the full year 2020 and provided corporate updates. Full Year 2020 Financial Highlights Total revenues increased 106% […] Lire la suite »

Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program

NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the U.S. Food and Drug Administration (FDA) has allowed evaluation of […] Lire la suite »

Tiziana Life Sciences plc: Accustem Update

NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, is pleased to confirm that, in order to finalise the distribution of shares in Accustem Sciences Limited (“Accustem“) to the […] Lire la suite »

Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting Covid-19, this therapeutic approach could be useful for newly identified Covid-19 variants in the UK, South Africa and Brazil. Foralumab is the first monoclonal antibody that can be […] Lire la suite »

Updated – Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021

NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, clarifies that its Chairman and Founder, Gabriele Cerrone, will be giving an interview on Bloomberg Television on Tuesday, 30 March […] Lire la suite »

Tiziana Life Sciences plc (“Tiziana” or the “Company”) – Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today

NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that the Chairman and founder, Gabriele Cerrone, will give an interview on Bloomberg Television on Monday, 29 March 2021 […] Lire la suite »

Ваша маска / респиратор фильтрует живые вирусы?

МИРАБЕЛЬ, Квебек, Канада, March 27, 2021 (GLOBE NEWSWIRE) — i3 Biomedical inc., корпорация по производству медицинского оборудования, сегодня публикует сравнительные результаты эффективности фильтрации живых вирусов с помощью многочисленных медицинских масок для лица и респираторов в прилагаемых таблицах. Для полного понимания результаты представлены в виде количества вирусов, вдыхаемых за минуту на […] Lire la suite »

LAVA Therapeutics Announces Pricing of Initial Public Offering

UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) — LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of its initial public offering of 6,700,000 common shares at a public […] Lire la suite »

Dyadic und Medytox entwickeln Impfstoffe gegen COVID-19-Varianten

Ausweitung der seit Juli 2020 bestehenden Zusammenarbeit im Bereich der COVID-19-Impfstoffforschung Medytox und Dyadic entwickeln gemeinsam COVID-19-Impfstoffe und/oder Booster aus C1, die Menschen gegen zwei oder mehr der aktuellen und zukünftigen COVID-19-Varianten immunisieren (d. h. tetravalente oder quadrivalente COVID-19-Impfstoffe) Exklusive Lizenz für die Republik Korea und mehrere südostasiatische Länder im […] Lire la suite »